Insights
Search Results
Client Highlights
6.02.26
Firm Advises Noctrix on Acquisition by Resmed
On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.
Client Highlights
4.08.26
Wilson Sonsini Advises HexemBio on $10.4 Million Seed Round
On April 7, 2026, HexemBio announced its public launch as a biotechnology company developing the breakthrough blood stem cell rejuvenation therapy, alongside the close of a $10.4 million seed round. The round is led by Draper Associates with participation from SOSV, Seraphim, and other strategic investors. The funding will be used to finalize HexemBio’s IND-enabling studies and GMP manufacturing, with the company targeting first-in-human trials in 2027. Wilson Sonsini Goodrich & Rosati advised HexemBio on the transaction.
Client Highlights
4.06.26
Wilson Sonsini Advises Soleno Therapeutics on $2.9 Billion Acquisition by Neurocrine
On April 6, 2026, Neurocrine Biosciences and Soleno Therapeutics announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
11.03.25
Wilson Sonsini Advises Pear Suite on $7.6 Million Series A Funding
On October 14, 2025, Pear Suite, a digital health company empowering community health workers, announced that it has raised $7.6 million in Series A funding. The investment round is led by Rock Health Capital and Nexxus Holdings, with support from Mucker Capital, Enable Ventures, The SCAN Foundation, Acumen America, Impact Engine, and the California Health Care Foundation. Wilson Sonsini Goodrich & Rosati advised Pear Suite on the transaction.
Client Highlights
10.31.25
Firm Advises Curve Biosciences on $40 Million Funding
On October 29, 2025, Curve Biosciences, the Whole-Body Intelligence™ company, announced it has raised $40 million in funding led by Luma Group with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others. The funding will advance the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform to transform chronic disease monitoring.
Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Wilson Sonsini Goodrich & Rosati advised Curve on the transaction. The team included Elton Satusky, Roy Argand, Davelyn Bulovas, and Isaac Reed.
Client Highlights
7.10.25
Firm Advises Soleno Therapeutics on $200 Million Public Offering
On July 10, 2025, Soleno Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the pricing of its previously underwritten public offering of 2,352,941 shares of its common stock at a public offering of $85.00 per share. Additionally, Soleno has granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price. The gross proceeds from the offering are expected to be approximately $200 million. The offering is expected to close on or about July 11, 2025. Banks including Goldman Sachs & Co. LLC and Guggenheim Securities acted as joint book-running managers. Wilson Sonsini Goodrich & Rosati is advising Soleno on the transaction.
Client Highlights
1.15.25
Wilson Sonsini Advises Aerin on $32.5 Million Equity Fundraise, New Debt Facility
On January 13, 2025, Aerin Medical, a medical device company focused on expanding access to meaningful relief for millions of patients suffering from chronic ENT conditions, announced the successful completion of two significant financial transactions. These transactions position Aerin Medical to drive additional commercial growth, advance market-leading innovation, and further expand its robust clinical evidence portfolio. The $32.5 million equity financing was led by all of Aerin's major investors: KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds, which also provided Aerin a debt facility to refinance its existing debt and access additional capital.
Client Highlights
1.15.25
Wilson Sonsini Advises Zeto, Inc. on $31 Million Series B
On January 8, 2025, Zeto, Inc., a medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and AI-driven cloud platform, announced the recent closing of a $31 million funding round led by MindWorks Global. The new funding will enable Zeto to expand its commercial and operational teams, drive further growth, and strengthen ongoing research and development efforts.
Client Highlights
11.26.24
Wilson Sonsini Advises Epic Cleantec on $12 Million Series B Funding
On November 21, 2024, Epic Cleantec (Epic), a leader in water reuse technology for the built environment, announced the close of its $12 million Series B funding round. The investment will accelerate the expansion of Epic’s pioneering water reuse and resource recovery solutions across a growing portfolio of projects, positioning Epic as one of the fastest-growing providers of water reuse systems for commercial and residential real estate globally. Recently ranked #1 on Fast Company’s Most Innovative Companies list (10-100 employees), Epic has successfully commissioned some of the first building-scale onsite reuse projects throughout the water-scarce U.S. West and will be the first to deploy onsite water reuse systems into high-rises in several major American cities across its national portfolio. Epic’s growing list of real estate and corporate clients includes notable names like Related, Salesforce, Crescent Heights, Westbank, Strada Investment Group, Alagem Capital, Kobayashi Group, and Stockdale Capital Partners.
Client Highlights
9.12.24
Wilson Sonsini Advises Circle Pharma on $90 Million Series D
On September 3, 2024, Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, announced the successful closing of a $90 million Series D financing round, which includes the conversion of a convertible note. The financing was led by The Column Group with participation from new and existing investors, including Nextech Invest and Euclidean Capital. The proceeds from the financing will be used to fund the clinical development of CID-078, Circle Pharma’s first-and-only-in-class cyclin A/B RxL inhibitor, and to support the development of the company’s portfolio of discovery programs built with its MXMO macrocycle platform.
Client Highlights
7.16.24
Wilson Sonsini Advises Digestiva on $18.4 Million Series A Financing
On July 15, 2024, Digestiva, a leading food biotech company, successfully closed its Series A equity financing round, raising $18.4 million. The round was led by Magdalena, a global leader in sugar cane processing, with participation from UC Investments, and existing investors The March Fund and Astanor. Digestiva's groundbreaking enzyme technology platform was initially discovered by co-founder Dr. Wilson Mak, in the lab of UC Davis faculty member Dr. Justin Siegel, a global leader in enzyme discovery, development, and design. Wilson Sonsini Goodrich & Rosati represented Digestiva in the transaction.
Client Highlights
5.06.24
Wilson Sonsini Advises Soleno Therapeutics on $138 Million Public Offering
On May 2, 2024, Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46 per share. The gross proceeds of the public offering are expected to be approximately $138 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The public offering is expected to close on or about May 7, 2024. Wilson Sonsini Goodrich & Rosati advised Soleno Therapeutics on the offering.